Anastomotic leak predicts diminished long-term survival after resection for gastric and esophageal cancer

Background Previous studies have reported on the association between perioperative morbidity and diminished oncologic outcomes in patients undergoing resection for colorectal or pancreatic cancer. However, the effect of anastomotic leak (AL) on the survival of patients with gastric or esophageal can...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Surgery 2016-07, Vol.160 (1), p.191-203
Hauptverfasser: Andreou, Andreas, MD, Biebl, Matthias, MD, Dadras, Mehran, MD, Struecker, Benjamin, MD, Sauer, Igor M., MD, Thuss-Patience, Peter C., MD, Chopra, Sascha, MD, Fikatas, Panagiotis, MD, Bahra, Marcus, MD, Seehofer, Daniel, MD, Pratschke, Johann, MD, Schmidt, Sven-Christian, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Previous studies have reported on the association between perioperative morbidity and diminished oncologic outcomes in patients undergoing resection for colorectal or pancreatic cancer. However, the effect of anastomotic leak (AL) on the survival of patients with gastric or esophageal cancer remains unclear. Methods Clinicopathologic data of patients who underwent resection for gastric or esophageal cancer between 2005 and 2012 were assessed, and predictors for overall survival and disease-free survival were identified. In addition, we evaluated the impact of AL on oncologic outcomes. Results Curative resection for gastric or esophageal cancer was performed in 471 patients. The primary tumor was located in the stomach and esophagus in 53% and 47% of the patients, respectively. Forty-one patients (8.7%) suffered an AL. The AL rate was significantly higher following resection for esophageal cancer compared with the resection for gastric cancer (12.9% vs 5.3%, P  = .001). Postoperative mortality (4%) was not significantly associated with the occurrence of AL (4% without AL vs 7% with AL, P  = .2). After a median follow-up time of 35 months, the median overall survival and disease-free survival were 101 and 93 months, respectively. Factors associated with worse overall survival in multivariate analysis included AL ( P  = .001), American Society of Anesthesiologists physical status ( P  
ISSN:0039-6060
1532-7361
DOI:10.1016/j.surg.2016.02.020